Loading...

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:11:24

HCW 2026: Two key recent papers have validated the...

BiotechTV - News ·

2026/09/14

Founder and CEO Amit Etkin describes the independent academic work that has been published on this and explains how ALTO-207, which is a combination of pramipexole and ondansetron, appears to have a more tolerable profile. Plus, an update on two other key programs

en-us

00:09:05

HCW 2026: Switzerland based Oculis focuses today on...

BiotechTV - News ·

2026/09/14

CEO Riad Sherif describes the phase 2 data Oculis delivered in optic neuritis with privosegtor last year and he previews data the company will have soon for licaminlamab in dry eye.

en-us

00:11:16

Bay Area based Shennon Biotechnologies announced a...

BiotechTV - News ·

2026/09/14

It also announced that the three lead programs will go after small cell lung cancer, ovarian, and hepatocellular carcinoma, though it did not disclose specific targets.

en-us

00:20:35

UC Berkeley's Gokul Upadhyayula and Eric Betzig are...

BiotechTV - News ·

2026/09/08

The work could help guide drug discovery and development by revealing how disease disrupts cells.

en-us

00:11:06

Bay Area based Moonwalk Biosciences announced a $70M...

BiotechTV - News ·

2026/09/08

Co-Founder and CEO Alex Aravanis discusses the need for improved treatments in the obesity space and why he thinks Moonwalk's RNAi platform is an ideal approach.

en-us

00:04:07

Cloverleaf Bio, a spinout out of Yale, announced $33M...

BiotechTV - News ·

2026/09/08

Co-Founders Austin Draycott and Cole Lewis, describe the type of work they are doing (the lead program targets hepatocellular carcinoma) and the investors that participated in the financing, which include 4BIO Capital, AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund.

en-us

00:07:57

Pareto Securities Healthcare Conference: Sedana...

BiotechTV - News ·

2026/09/02

CEO Johannes Doll describes what he believes are the advantages of an inhaled sedative vs the traditional IV. The company already has experience commercializing this in Europe, with 1 out of 7 ICU patients in Germany currently using it. The U.S. PDUFA date is April 16.

en-us

00:05:05

Pareto Securities Healthcare Conference: Pareto's Dan...

BiotechTV - News ·

2026/09/02

He says that capital is returning to the sector and that investors have been doing more scientific due diligence recenetly. Plus, the impact of AI on biotech.

en-us

00:33:54

Congressman Jake Auchincloss discusses the economic...

BiotechTV - News ·

2026/09/02

Interviewed by MassBio CEO Kendalle Burlin O'Connell, Congressman Auchincloss of Massachusetts describes the impact he believes a tightening of funding for basic research is having on our industry and measures he would take to bolster innovative research. He advocates for making it easier to run early stage clinical trials in the U.S. and for it to be less costly for small biotech companies to engage with FDA.

en-us

00:07:34

Pareto Securities Healthcare Conference: BioInvent...

BiotechTV - News ·

2026/09/02

CEO Martin Welschof walks us through recent ASCO (ovarian in combo with Keytruda) and EHA (CTLC) data for BI-1808, and describes why the company believes TNFR2 is a compelling checkpoint with wide applicability. Plus, BI-1206 (FcyRIIB), which will have NCSLC data later this year and BioInvent ultimately hopes to partner.

en-us

00:12:09

Pareto Securities Healthcare Conference: Orexo...

BiotechTV - News ·

2026/09/02

CEO Nikolaj Sørensen walks us through all the potential benefits of delivering medicines via a nasal spray, would theoretically could even include the ability to cross the BBB for CNS conditions. Naloxone and epinephrine are the most advance, and Orexo also has plans for a nasal spray GLP and vaccines.

en-us

00:10:58

Pareto Securities Healthcare Conference: Hansa...

BiotechTV - News ·

2026/09/02

CEO Renée Aguiar-Lucander describes the idea behind imlifidase and discusses the trial that led to the U.S. filing. Hansa has also recently confidentially filed for an IPO in the United States as well.

en-us

00:07:50

Pareto Securities Healthcare Conference: Mendus'...

BiotechTV - News ·

2026/09/02

CEO Erik Manting describes vididencel and the progress the company has been making in AML, CML, and ovarian cancer. Additional CML data is expected in this second half of the year.

en-us

00:13:06

A focus on cutting edge science and a busy year of...

BiotechTV - News ·

2026/09/01

Co-Founder & CEO Erik Wiklund highlights the potential of circular RNA and walks us through the work Circio is doing in gene and cell therapy, including heart and eye indications, CNS, and in vivo CAR-T. The company has raised approximately $65M USD this year, putting at the top of European biotech raises.

en-us

00:13:06

Sweden's BioArtic founded the science behind the...

BiotechTV - News ·

2026/09/01

CEO Gunilla Osswald talks about the recently approved self-administered subcu formulation of lecanemab, called IQLIK, and updates us on a Parkinson's program that is moving along. Plus, how BioArctic's transferrin based brain transporter technology is different than others, which has resulted in numerous prestigious pharma partnerships.

en-us

00:09:21

Remix Therapeutics announced earlier this summer...

BiotechTV - News ·

2026/08/26

Co-Founder and CEO Pete Smith describes how Remix uses small molecules to stop the transcription of disease causing mRNAs. The lead program targets MYB and is in a phase 1/2 for adenoid cystic carcinoma. The reverse merger could close towards the end of year.

en-us

00:40:01

Two fathers of children with rare diseases talk about...

BiotechTV - News ·

2026/08/26

Interviewed by MassBio CEO Kendalle Burlin O'Connell, Ilan Ganot describes co-founding Solid Biosciences in honor of his child with Duchenne muscular dystrophy and Daniel Fischer discusses co-founding Tevard Biosciences in honor of his child with Dravet syndrome.

en-us

00:16:43

LifeMine Therapeutics announced a $263M raise today...

BiotechTV - News ·

2026/08/06

Co-Founder, President & CEO Greg Verdine describes the toxicity issues associated with the immuosupressive drugs that transplant recipients currently receive, and explains how LIFE-001 is different. Plus, given how the therapy is designed to safely prevent T-cell activation and proliferation, there could also ultimately be an autoimmune use case as well.

en-us

00:15:20

U.S. Science Summit: Biotech veteran Harvey Berger...

BiotechTV - News ·

2026/07/27

Dr. Berger, who founded Ariad Pharmaceuticals here in 1991, describes Kendall's transition from candy factories, to Polaroid, to what it is today.

en-us

00:23:31

U.S. Science Summit: Patient perspectives with sickle...

BiotechTV - News ·

2026/07/27

Jim Olaghere describes signing up for a gene editing treatment clinical trial for sickle cell disease and how it has enabled him to climb mountains and Bob Coughlin recounts the moment when a therapy became available for his son's cystic fibrosis.

en-us

485 results

Similar Podcasts

Science Weekly

The Guardian

La Science CQFD

France Culture

The Dirt: an eKonomics podKast

eKonomics

La Science, CQFD

France Culture

Travelers In The Night

Albert D. Grauer